Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant type III humanized collagen injection for facial skin condition improvement
ChiCTR2200066696Phase 3Not yet recruiting
- Sponsor
- Plastic Surgery Hospital of Chinese Academy of Medical Sciences
- Start
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of recombinant human type III collagen in cutaneous aging and Asteatosis (2 arms), sponsored by Plastic Surgery Hospital of Chinese Academy of Medical Sciences. Primary endpoint: Global Aesthetic Improvement Scale. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
recombinant human type III collagen
03
Conditions
cutaneous agingAsteatosis
Beyond the preview
Go deeper on ChiCTR2200066696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066696.